ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $50,136,726 | -13.0% | 2,405,793 | 0.0% | 4.74% | +1.9% |
| Q2 2023 | $57,618,742 | +27.3% | 2,405,793 | 0.0% | 4.66% | +24.1% |
| Q1 2023 | $45,277,024 | +19.7% | 2,405,793 | +1.2% | 3.75% | +16.3% |
| Q4 2022 | $37,831,794 | +37.8% | 2,376,369 | +41.6% | 3.23% | +48.6% |
| Q3 2022 | $27,455,000 | +16.1% | 1,678,196 | 0.0% | 2.17% | +5.3% |
| Q2 2022 | $23,646,000 | -56.6% | 1,678,196 | -25.5% | 2.06% | -51.1% |
| Q1 2022 | $54,539,000 | -0.0% | 2,251,834 | -3.7% | 4.22% | +20.9% |
| Q4 2021 | $54,566,000 | +40.5% | 2,337,877 | 0.0% | 3.49% | +48.8% |
| Q3 2021 | $38,832,000 | -31.9% | 2,337,877 | 0.0% | 2.34% | -25.4% |
| Q2 2021 | $57,021,000 | -5.5% | 2,337,877 | 0.0% | 3.14% | -8.6% |
| Q1 2021 | $60,317,000 | -51.0% | 2,337,877 | +1.6% | 3.44% | -46.7% |
| Q4 2020 | $123,037,000 | +62.8% | 2,301,477 | +25.6% | 6.45% | +55.5% |
| Q3 2020 | $75,582,000 | -0.4% | 1,832,300 | +17.1% | 4.15% | -8.9% |
| Q2 2020 | $75,851,000 | +10.0% | 1,564,900 | -4.1% | 4.55% | -21.1% |
| Q1 2020 | $68,932,000 | -15.4% | 1,631,524 | -14.4% | 5.77% | +28.6% |
| Q4 2019 | $81,512,000 | +4.1% | 1,905,374 | -12.5% | 4.49% | -14.0% |
| Q3 2019 | $78,339,000 | +26.9% | 2,176,677 | -5.7% | 5.22% | +73.9% |
| Q2 2019 | $61,714,000 | +2.2% | 2,308,803 | +2.7% | 3.00% | +19.1% |
| Q1 2019 | $60,370,000 | +84.3% | 2,248,403 | +11.0% | 2.52% | +44.4% |
| Q4 2018 | $32,761,000 | -6.3% | 2,026,063 | +20.3% | 1.74% | +23.4% |
| Q3 2018 | $34,964,000 | +38.7% | 1,684,180 | +2.0% | 1.41% | +40.3% |
| Q2 2018 | $25,207,000 | -32.0% | 1,650,780 | 0.0% | 1.01% | -36.5% |
| Q1 2018 | $37,093,000 | -24.9% | 1,650,780 | +0.6% | 1.59% | -25.5% |
| Q4 2017 | $49,411,000 | -20.1% | 1,641,030 | 0.0% | 2.13% | -18.3% |
| Q3 2017 | $61,818,000 | +37.4% | 1,641,030 | +1.7% | 2.60% | +23.9% |
| Q2 2017 | $44,996,000 | -17.7% | 1,613,330 | +1.4% | 2.10% | -18.7% |
| Q1 2017 | $54,679,000 | +23.8% | 1,590,430 | +3.8% | 2.58% | +2.5% |
| Q4 2016 | $44,184,000 | -6.3% | 1,532,030 | +3.4% | 2.52% | -7.9% |
| Q3 2016 | $47,140,000 | +1.0% | 1,481,930 | +3.1% | 2.74% | -22.3% |
| Q2 2016 | $46,669,000 | +244.1% | 1,437,730 | +196.4% | 3.52% | +234.8% |
| Q1 2016 | $13,563,000 | – | 485,100 | – | 1.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |